ZLAB stock sentiment todayZai Lab Ltd
Sentiment verdict
Gossip first, financials second — NEUTRAL at 75% confidence.
Last updated · cached analysis, refreshes periodically
ZLAB
Zai Lab LtdA high-growth bridge between Western biotech and the Chinese market, currently hampered by geopolitical risk and a high cash burn rate.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for ZLAB. Not financial advice.
Price · last 12 months
Gossip
Market narrative is split between Zai Lab's impressive commercial execution (VYVGART launch) and persistent concerns over US-China legislative tensions (BIOSECURE Act). Investors are closely watching the path to profitability by 2025.
- ·Launch momentum of Vyvgart in China
- ·Geopolitical friction affecting US-listed Chinese firms
- ·Shift from R&D-stage to commercial-stage biotech narrative
Financial
Strong top-line revenue growth (exceeding 40% YoY) driven by a portfolio of licensed blockbusters, supported by a healthy $700M+ cash position, though the bottom line remains in the red due to high SG&A and R&D spend.
- ·Revenue growth: ~40% year-over-year
- ·Cash runway: Sufficient through 2026
- ·Net Margin: Negative, but narrowing losses
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Hollow — insiders are stepping back and the register is short-horizon.
- ·Insiders sold a net $637K on the open market in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·Geopolitical regulatory changes (Delisting risks or Biosecure Act impacts)
- ·Dependence on third-party licenses for core pipeline
- ·Pricing pressures from China's National Reimbursement Drug List (NRDL)
Peer temperature
How direct competitors stack up against ZLAB right now.
- HOTBGNEBeiGene, Ltd.
HOTTER — larger scale, superior global footprint with internal R&D successes like Brukinsa, and stronger institutional backing.
See full analysis → - NEUTRALHUTCHHUTCHMED (China) Ltd
SIMILAR — also navigating the China-to-Global oncology bridge, but with a more mature internal manufacturing capability.
See full analysis → - COLDLABUDirexion Biotech Bull 3X (Proxy for XBI)
COLDER — ZLAB offers specific commercial execution alpha compared to the broader biotech sector which is struggling with high interest rates.
See full analysis →
- ZLAB+42.4%
- BGNE—
- HUTCH—
- LABU+29.9%
AI-generated analysis for informational purposes only. Not financial advice.